Francesco Fioretti,Jeffrey M Testani,Maria Clarissa Tio et al.
Francesco Fioretti et al.
Chronic renin-angiotensin-aldosterone system activation and excess aldosterone exert detrimental effects on the heart and the kidneys via contributing to inflammation, fibrosis, and dysfunction in the myocardium, vasculature, and the kidney...
Andrew S Perry,Lynne W Stevenson
Andrew S Perry
Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure With Improved Ejection Fraction [0.03%]
射血分数改善的心力衰竭患者经指南指导的最佳药物治疗的结局
Kyung H Min,Alan S Go,Keane Lee et al.
Kyung H Min et al.
Background: The prevalence of heart failure with improved ejection fraction (HFimpEF) is anticipated to increase with the availability and implementation of novel pharmacotherapy for heart failure with reduced ejection fr...
Combining SGLT2i and MRAs in Heart Failure: Playing the Long Game [0.03%]
心力衰竭中SGLT2抑制剂与MRAs联合使用：长期策略
Muthiah Vaduganathan,Brendon L Neuen
Muthiah Vaduganathan
Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction: The SOGALDI-PEF Trial [0.03%]
钠-葡萄糖共转运蛋白2抑制剂联合或不联合醛固酮拮抗剂治疗射血分数保留的心力衰竭：SOGAL-HFPEF试验
João Pedro Ferreira,Francisco Vasques-Nóvoa,Francisca Saraiva et al.
João Pedro Ferreira et al.
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists improved heart failure outcomes in heart failure with mildly reduced ejection fraction or heart failure with preser...
Randomized Controlled Trial
Journal of the American College of Cardiology. 2025 Aug 5;86(5):320-333. DOI:10.1016/j.jacc.2025.05.033 2025
Harlan M Krumholz
Harlan M Krumholz
Intra-Aortic Balloon Pump in Heart Failure-Related Cardiogenic Shock: Dead or Alive? [0.03%]
心源性休克患者的主动脉内球囊泵应用：救死扶伤还是雪上加霜？
Luca Baldetti,Silvia Ajello,Mario Gramegna et al.
Luca Baldetti et al.
Farooq H Sheikh,Chongshu Chen,Emre Aldinc et al.
Farooq H Sheikh et al.
Anshul Yadav,Ojus Yadav,Neelesh Gupta et al.
Anshul Yadav et al.
Reply: Are Benefits of Early Ezetimibe Conferred by its Effect on LDL-C? [0.03%]
答：依折麦布早期应用的获益是通过降低LDL-C实现的吗？
Margret Leosdottir,Kausik K Ray,Tomas Jernberg et al.
Margret Leosdottir et al.